Medical
-
A study published July 13, 2015 in the Journal of Clinical investigation demonstrated that an inhaled vaccine created by a team from The University of Texas Medical Branch at Galveston (UTMB) and the National Institutes… Read more . . .
-
According to the authors of an article published in The BMJ on July 1, 2015, the Global Initiative for Obstructive Lung Disease (GOLD) criteria for COPD diagnosis result in significant overdiagnosis and overprescription of inhalers,… Read more . . .
-
A study published online in CHEST on June 25, 2015 finds that discontinuing inhaled corticosteroids for COPD patients reduced the risk of pneumonia by 37%, with the greatest reduction in risk associated with stopping inhaled… Read more . . .
-
OptiNose has announced positive results from the 24-week Phase 3 trial of OPN-375, an intranasal fluticasone product for the treatment for nasal polyps based on the company’s Bi-Directional Breath-Powered delivery system. The study showed statistically… Read more . . .
-
A study published online June 11 2015 in the American Journal of Respiratory and Critical Care Medicine showed that asthma patients over 30 years of age who were using inhaled corticosteroids experienced a greater proportion… Read more . . .
-
AmpliPhi BioSciences has announced that a study performed in conjunction with the Royal Brompton Hospital and Imperial College, UK showed that a variety of bacteriophages remain viable against P. aeruginosa after nebulization. Three different commercially… Read more . . .
-
Novartis has announced positive results from several Phase 3 studies of NVA237 glycopyrronium bromide and QVA149 indacaterol/glycopyrronium bromide, both delivered by the Breezhaler DPI for the treatment of COPD. NVA237 is marketed as Seebri Breezhaler… Read more . . .
-
Sunovion Pharmaceuticals has presented results from three studies of Brovana arformoterol tartrate inhalation solution for the treatment of COPD at ATS 2015. According to Sunovion, the studies show that Brovana produces clinically significant improvement in… Read more . . .
-
Boehringer Ingelheim Pharmaceuticals has presented new data analyses from two Phase 3 studies of its tiotropium/olodaterol Respimat SMI for the treatment of COPD at ATS 2015. The two efficacy and safety studies (NCT01431274 and NCT01431287),… Read more . . .
-
Discovery Laboratories has announced that data from a Phase 2a clinical trial of Aerosurf aerosolized KL4 surfactant for the treatment of respiratory distress syndrome (RDS) in premature infants show that the novel delivery technology performed… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden